Rockwell Medical (RMTI) Posts Earnings Results, Misses Estimates By $0.05 EPS

Rockwell Medical (NASDAQ:RMTI) released its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05), Bloomberg Earnings reports. Rockwell Medical had a negative net margin of 39.28% and a negative return on equity of 46.63%. The firm had revenue of $14.80 million for the quarter. During the same quarter in the prior year, the firm earned ($0.10) earnings per share. Rockwell Medical’s quarterly revenue was up 10.5% compared to the same quarter last year.

Shares of Rockwell Medical (RMTI) traded down $0.54 during mid-day trading on Thursday, reaching $6.22. 448,960 shares of the company’s stock traded hands, compared to its average volume of 258,578. The company has a market capitalization of $336.96, a price-to-earnings ratio of -14.46 and a beta of 2.04. Rockwell Medical has a twelve month low of $4.84 and a twelve month high of $8.98.

RMTI has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Rockwell Medical from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. BidaskClub raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Finally, ValuEngine lowered shares of Rockwell Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd.

TRADEMARK VIOLATION WARNING: This report was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at

About Rockwell Medical

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Earnings History for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with's FREE daily email newsletter.

Leave a Reply